Close Menu

Tempus

The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. 

Tempus is developing a new predictive bioinformatics model to improve clinical trial enrollment for Janssen, while the pharma firm has joined Tempus' TIME Trial.

PanCAN has partnered with Tempus to provide panel genomic testing for every patient enrolled in the Precision Promise platform study.

Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.

Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

The company believes that helping to funnel patients to the trial will help support its own goals to gather genomic information on targeted cancer therapy efficacy.

After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.